 |
| Kontakta oss |
|
| sanofi-aventis |
Gustavslundsvägen 139
Box 14142
167 14 BROMMA, Sverige
Tfn.: (+46) 08-634 50 00
|
| Kontakta oss |
|
|
|
|
 | Pressreleaser 2010 |
|
 | Denna information riktar sig till journalister och media. |
|
|
|
| 30 augusti 2010 |
| Var fjärde svensk över 40 år kommer att drabbas av förmaksflimmer |
| I takt med en åldrande befolkning beräknas var fjärde svensk över 40 år insjukna i förmaksflimmer under sin livstid. Trots det vet endast fyra av tio vilka symtom sjukdomen är förknippad med, visar en undersökning med över tusen svenskar.
|
|
|
| 30 augusti 2010 |
| Nya europeiska riktlinjer för behandling av förmaksflimmer presenterades igår |
| I dagarna hålls den europeiska hjärtkongressen ESC (European Society of Cardiology) i Stockholm. Under kongressens fyra dagar presenteras nya riktlinjer för hjärtsjukvård. Nya data har föranlett en revidering av de tidigare riktlinjerna från 2006.
|
|
|
| 30 augusti 2010 |
| Teriflunomide Significantly Reduced Annualized Relapse Rate and was well Tolerated in MS patients |
| First results from the TEMSO phase III trial to be presented during the ECTRIMS congress in October 2010
|
|
|
| 29 augusti 2010 |
| Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme |
- $69 Per Share All-Cash Offer Represents Immediate and Certain Value and a Significant Premium for Genzyme Shareholders
- Transaction Would Help Genzyme Achieve its Vision of Making a Positive Impact on the Lives of People with Serious Diseases
- Transaction Would Enhance sanofi-aventis’ Sustainable Growth Strategy
|
|
|
| 26 augusti 2010 |
| Sanofi-aventis Comments on Injunctive Relief Hearing Regarding Lovenox® |
|
|
|
|
| 29 juli 2010 |
| EPS growth in Q2 2010 |
|
|
|
|
| 27 juli 2010 |
| Sanofi-aventis and Merck appoint Raul Kohan as CEO for the new Animal Health joint venture |
| Proposed JV to be called Merial-Intervet.
|
|
|
| 23 juli 2010 |
| Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium in the U.S. |
|
|
|
|
| 19 juli 2010 |
| Jevtana® (cabazitaxel) Injection Now Available in the U.S. |
| Jevtana plus prednisone is the first and only therapy approved for patients with metastatic hormone-refractory prostate cancer previously treated with docetaxel-based therapy.
|
|
|
| 01 juli 2010 |
| Sanofi-aventis and JDRF Form Partnership to Improve Therapies, Work Toward Cure for Type 1 Diabetes |
|
|
|
|
| 01 juli 2010 |
| Rifapentine is granted Orphan Drug Status by European Commission for Treatment of Tuberculosis |
| Shorter treatment duration with rifapentine expected to bring significant benefits to patients.
|
|
|
| 30 juni 2010 |
| Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical company |
| Development of oral potent oncology medicines for the treatment of hematological malignancies.
|
|
|
| 26 juni 2010 |
| Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin |
| Study Findings Presented at American Diabetes Association’s 70th Annual Scientific Sessions.
|
|
|
| 25 juni 2010 |
| Improved Outcomes for Patients Treated with Lantus® and Apidra® Regimen Compared with Sliding Scale Insulin |
| Study Results Presented at American Diabetes Association’s 70th Annual Scientific Sessions.
|
|
|
| 25 juni 2010 |
| Sanofi-aventis and Metabolexenter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II Diabetes |
| New oral agent has a dual mechanism of action affecting both insulin and GLP-1 release.
|
|
|
| 22 juni 2010 |
| Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics |
| Collaboration starting with a specific lead in Fibrosis.
|
|
|
| 17 juni 2010 |
| Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority Review |
| First and only therapy to provide significant survival benefit in second-line metastatic hormone-refractory prostate cancer.
|
|
|
| 08 juni 2010 |
| Sanofi Pasteur partners with Vivalis for the discovery of human monoclonal antibodies against infectious diseases |
|
|
|
|
| 05 juni 2010 |
| Teriflunomide in adjunct to interferon beta significantly improved outcomes of Multiple Sclerosis patients |
| One-year Phase II data presented at the 2010 ACTRIMS meeting.
|
|
|
| 04 juni 2010 |
| Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in Oncology |
| Small molecules could restore Tumor Cell Apoptosis by reactivating tumor suppressor functions of the p53 gene.
|
|
|
| 31 maj 2010 |
| The Charité University in Berlin and sanofi-aventis Sign an Innovative Research Cooperation Agreement |
| First Public-Private Research Partnership of this kind in Germany.
|
|
|
| 28 maj 2010 |
| Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in Japan |
|
|
|
|
| 27 maj 2010 |
| Updated Phase 3 Survival Results with Cabazitaxel in Patients with Advanced Hormone-Refractory Prostate Cancer, Presented at ASCO |
| Results Demonstrated 28% Improvement in Overall Survival.
|
|
|
| 26 maj 2010 |
| Sanofi-aventis Establishes Strategic Alliance with MIT’s Center for Biomedical Innovation |
| Alliance formed to advance cutting-edge research and foster collaboration between academia and industry.
|
|
|
| 25 maj 2010 |
| Sanofi-aventis Wins the 2010 Global Business Coalition Core Competence Award for its Innovative Malaria Access to Medicines Program |
|
|
|
|
| 21 maj 2010 |
| Sverige satsar på behandling av förmaksflimmer |
| Tandvårds- och läkemedelsförmånsverket (TLV) har beslutat att MULTAQ® (dronedaron) från och med den 18 maj 2010 är subventionerat inom läkemedels-förmånen med begränsning. Dronedaron är det första nya läkemedlet på över 10 år som lanseras i Sverige för behandling av förmaksflimmer.
|
|
|
| 19 maj 2010 |
| Sanofi-aventis to reinforce its consumer health care platform in Poland |
| Sanofi-aventis Launches Public Tender for Nepentes S.A
|
|
|
| 17 maj 2010 |
| Combined General Shareholder Meeting of May 17, 2010 |
- Serge Weinberg appointed Chairman of the Board of Directors
- Jean-François Dehecq appointed Honorary Chairman of sanofi-aventis
- 2.40 Euros per share dividend (+9.1%) payable on May 25, 2010
|
|
|
| 17 maj 2010 |
| Sanofi-aventis announces the creation of the "Sanofi Espoir" corporate foundation |
- Commitment to Health and Solidarity
- Jean-François Dehecq appointed President of the Foundation
|
|
|
| 12 maj 2010 |
| Sanofi-aventis påbörjar studie av 10 000 patienter som får Multaq® som behandling av kroniskt förmaksflimmer |
| Ny utfallstudie som syftar till att utöka evidensen för dronedaron i en annan population med förmaksflimmer
|
|
|
| 03 maj 2010 |
| Sanofi-aventis and Glenmark Pharmaceuticals sign license agreement on novel agents to treat chronic pain |
|
|
|
|
| 30 april 2010 |
| Change in sanofi-aventis Executive Committee |
|
|
|
|
| 29 april 2010 |
| Q1 2010: A good first quarter |
|
|
|
|
| 23 april 2010 |
| Sanofi-aventis announces court decision resolving Eloxatin® U.S. patent litigation |
| Eloxatin® expected to recover in the U.S. Market.
|
|
|
| 15 april 2010 |
| Once daily Lixisenatide (AVE 0010) given as monotherapy successfully meets phase III study endpoints in diabetes |
- Lixisenatide significantly reduced HbA1c vs placebo with more patients achieving HbA1c <7%
- Significant effect on postprandial glucose
|
|
|
| 12 april 2010 |
| Sanofi Pasteur partners with U.S. naval medical research center to advance development of travelers’ diarrhea vaccine |
| The licensed technology was developed by the NMRC with the help of the University of Colorado.
|
|
|
| 08 april 2010 |
| Sanofi-aventis and CureDM sign exclusive worldwide license agreement on novel regenerative compound to treat diabetes |
| New Human Peptide Sequence for Regenerative Medicine Application.
|
|
|
| 08 april 2010 |
| Board of Directors of sanofi-aventis |
|
|
|
|
| 06 april 2010 |
| Sanofi-aventis makes updated settlement announcement regarding Eloxatin® U.S. Patent litigation |
|
|
|
|
| 05 april 2010 |
| Sanofi-aventis Amends its alliance agreement with Warner Chilcott regarding Actonel® (risedronate sodium) in the United States and Puerto Rico |
| Warner Chilcott to Assume Full Commercial Responsibility
|
|
|
| 01 april 2010 |
| Sanofi-aventis Announces Settlement of Eloxatin® U.S. Patent litigation |
|
|
|
|
| 31 mars 2010 |
| Sanofi-Aventis invests €150 million in France and continues its change towards biotechnologies |
- Creation of the Group 3rd largest European vaccine production center in Neuville-sur-Saône
- Biotechnology training programs for 700 employees
- Steady number of industry jobs in France over the next four years
|
|
|
| 31 mars 2010 |
| Sanofi-aventis & AgaMatrix enter into worldwide agreement on blood glucose monitoring (BGM) solutions |
| Partnership to Contribute to Improved Quality of Diabetes Care.
|
|
|
| 30 mars 2010 |
| Multaq® receives positive recommendation by NICE in new appraisal consultation document |
|
|
|
|
| 29 mars 2010 |
| Sanofi-aventis bekräftar kvalitet och leverans av Plavix® |
|
|
|
|
| 25 mars 2010 |
| DuoPlavin®/DuoCover® Dual antiplatelet combination tablet newly approved in the European Union |
|
|
|
|
| 11 mars 2010 |
| Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc. |
| Chattem becomes the U.S. Consumer Healthcare Platform for sanofi-aventis.
|
|
|
| 09 mars 2010 |
| Cabazitaxel förbättrar överlevnaden hos patienter med avancerad hormonrefraktär prostatacancer |
| Resultat som har observerats hos patienter som behandlats med cabazitaxel i kombination med prednison vars sjukdom har progredierat trots tidigare docetaxel-baserad kemoterapi. Data från en stor internationell fas-III studie vid 2010 års Genitourinary Cancers Symposium i San Francisco
|
|
|
| 09 mars 2010 |
| Sanofi-aventis and Merck to create a Global Leader in Animal Health |
| Sanofi-aventis exercises its option to combine Merial with Intervet/Schering-Plough in a new equally-owned Joint Venture with Merck.
|
|
|
| 02 mars 2010 |
| Board of Directors of sanofi-aventis |
|
|
|
|
| 19 februari 2010 |
| Sanofi Pasteur’s A(H1N1) vaccine HUMENZA®* recommended by European Medicines Agency |
|
|
|
|
| 17 februari 2010 |
| Sanofi-aventis strengthens commitment to research in France through partnership with AVIESAN |
- First Partnership Agreement to be signed with all players of the French Academic Research community
- Financial support of young research laureates of the ATIP AVENIR sponsorship programme from CNRS and INSERM
- Investment of up to 50 million Euros over five years in public-private partnerships
|
|
|
| 15 februari 2010 |
| My child matters Supports Seven New Childhood Cancer Care Projects |
| In Cameroon, Ecuador, Mozambique, Panama and Thailand
|
|
|
| 15 februari 2010 |
| Sanofi-aventis’ ClikSTAR® reusable insulin pen for Lantus® and Apidra® receives the prestigious GOOD DESIGN Award |
|
|
|
|
| 10 februari 2010 |
| Sanofi-aventis presenterar goda resultat för 2009 |
|
|
|
|
| 29 januari 2010 |
| Sanofi-aventis Signs Agreements to Establish New Consumer Healthcare Joint Venture in China with Minsheng Pharmaceutical Group |
- Sanofi-aventis Poised to Enter the Dynamic
Consumer Healthcare Market in China -
|
|
|
| 26 januari 2010 |
| Sanofi-aventis obtains antitrust clearance in connection with Chattem, Inc. tender offer |
|
|
|
|
| 22 januari 2010 |
| Sanofi-aventis och dess medarbetare samverkar till förmån för Haitis offer |
• 1 miljon euro till återuppbyggnad
• Akut ekonomiskt stöd och betydande donationer av medicin och vaccin
• Medarbetarnas generositet matchas av koncernen
|
|
|
| 11 januari 2010 |
| Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections |
| - The Antibody Fragment Could Prevent and Treat Pneumonia in High-Risk Patients -
|
|
|
| 11 januari 2010 |
| Sanofi-aventis Commences Tender Offer for all Outstanding Shares of Chattem, Inc. |
|
|
|
|
| 08 januari 2010 |
| Sanofi-aventis reinforces its Consumer Health Care Management |
|
|
|
|
|
|
